SynthesisBreast cancer research and treatment2019
Primary and secondary breast angiosarcoma: single center report and a meta-analysis.
Synthesis in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 97 citations in OpenAlex.
- Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes.Annals of surgical oncology · 2026Article
- Socioeconomic Status and Survival in Sarcomas of the Breast: Nationwide Cohort Study.Annals of surgical oncology · 2026Article
- Prognostic significance of clinicopathological parameters, margin width and locoregional recurrences on outcome of primary and radiation associated breast angiosarcoma- results from a large UK sarcoma regional service.Breast cancer research : BCR · 2026Article
- Breast Hemangioma with Slow Growth over 11 Years: A Case Report.Reports (MDPI) · 2026Article
- Case Report: Metachronous bilateral primary and secondary angiosarcoma of the breast.Frontiers in oncology · 2026Article
- Trends in the incidence, survival, and prognostic nomogram of angiosarcoma in the United States.Medicine · 2025Article
- Radiation-associated breast angiosarcoma after strut-adjusted volume implant brachytherapy.Radiology case reports · 2024Article
- Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.Breast cancer (Tokyo, Japan) · 2024Article
- Article
- Primary angiosarcoma of the breast in a 21-year-old female: A case report.SAGE open medical case reports · 2024Article
- Renal pelvis metastasis following surgery for breast angiosarcoma: a case report and literature review.Frontiers in oncology · 2024Article
- A rare case of radiation-induced breast angiosarcoma: a case report.Case reports in plastic surgery & hand surgery · 2024Article
- Usefulness of machine learning and deep learning approaches in screening and early detection of breast cancer.Heliyon · 2023Review
- Multiple angiosarcomas of both breasts: a case report.Surgical case reports · 2023Article
- Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.BMC cancer · 2023Article
- Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive Entities.Cancers · 2023Review
- Primary Breast Sarcoma: A Two-Centre Analysis and Review of Literature.Breast care (Basel, Switzerland) · 2023Article
- Clinicopathological characteristics and survival outcomes in patients with angiosarcoma of breast.Cancer medicine · 2023Article
- Angiosarcoma of the Breast: Overview of Current Data and Multimodal Imaging Findings.Journal of imaging · 2023Review
- A case report of primary angiosarcoma of the breast.Translational cancer research · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPrimary and secondary breast angiosarcoma is a rare and aggressive malignancy with limited published literature. Optimal management is mostly based on expert opinion. Our study aims to describe a single institution experience with breast angiosarcoma and evaluate other publications on this topic to further clarify prognostic outcomes and treatment modalities in this disease.
methodsTwenty two cases of breast angiosarcoma from Roswell Park Comprehensive Cancer Center were retrospectively analyzed. Additionally, a systemic review and meta-analysis was conducted to study the association between survival outcomes, overall survival (OS), and recurrence-free survival (RFS) in both primary (PAS) and secondary breast angiosarcoma (SAS).
results9 PAS patients (41%) and 13 SAS patients (59%) were retrospectively analyzed. No significant differences were noted in tumor characteristics and survival outcomes between PAS and SAS. Treatment modality had no significant effects on survival outcomes although adjuvant chemotherapy demonstrated a trend towards improved RFS in high grade tumors. 380 PAS and 595 SAS patients were included in the outcome meta-analysis. Survival outcomes were significantly worse with high grade tumors and tumor size of > 5 cm. Adjuvant radiation therapy demonstrated significantly better RFS, while adjuvant chemotherapy had no effect on survival outcomes.
conclusionTumor size and grade seem to be reliable predictors of survival in both PAS and SAS. Mastectomy does not seem to be adding any additional benefit to BCS. Adjuvant radiation therapy showed statistically significant RFS benefit, while adjuvant chemotherapy can be beneficial in high grade tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.